Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 173
- Registration Number
- NCT02024789
- Locations
- 🇮🇹
Policlinico Universitario "Agostino Gemelli";Dip. Tutela Salute Donna Bambino Adolescente, Roma, Lazio, Italy
🇲🇽Clínica Para la Atención del Neurodesarrollo, Aguascalientes, Mexico
🇲🇽Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria, Monterrey, Mexico
A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 42
- Registration Number
- NCT02023125
A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT02019329
A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT02019290
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02019277
- Locations
- 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺St George Hospital; Cancer Care Centre, Kogarah, New South Wales, Australia
🇦🇺Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia
A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of RO6864018 in Male, Healthy, Asian Participants
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT02015715
- Locations
- 🇸🇬
Changi General Hospital; Clinical Trial & Research unit, Singapore, Singapore
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 69
- Registration Number
- NCT02015676
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
- Conditions
- Liver Cancer
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02013830
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02013206
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02013219
- Locations
- 🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇭🇰The Chinese University of Hong Kong, Shatin, Hong Kong